Atlas Trials

Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma

Clinical trial NCT05507632 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05507632
Sponsor
Nanfang Hospital, Southern Medical University
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Unresectable Hepatocellular Carcinoma
Start date
2022-08-18
Primary completion
2026-03-26
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.